REG - Oxford Nanopore Tech - Oxford Nanopore and Cepheid collaboration

Oxford Nanopore TechnologiesAnnouncement

09/04/2025 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250409:nRSI3384Ea&default-theme=true

RNS Number : 3384E  Oxford Nanopore Technologies plc  09 April 2025

9 April 2025

Oxford Nanopore Technologies plc

Oxford Nanopore and Cepheid partner to advance automated sequencing-based
solutions

 

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company
delivering a new generation of molecular sensing technology based on
nanopores, and Cepheid, a leading molecular diagnostics company, today
announced a strategic collaboration to develop and commercialise a seamless
end-to-end workflow to advance the field of sequencing for infectious
diseases.

 

The two companies have completed a successful proof-of-concept study which
demonstrated the feasibility of using Cepheid's cartridge-based GeneXpert
system for sample and library preparation in a workflow with Oxford Nanopore's
molecular analysis platform. The positive results from the proof-of-concept
have paved the way for the strategic collaboration to develop and launch a
joint Research Use Only 1  (RUO) workflow that will enable customers to
leverage rapid, information-rich sequencing in-house for infectious disease
analysis, returning results within hours instead of days.

 

The collaboration is intended to deliver a scalable, automated, end-to-end
solution for simplified nanopore-based sequencing workflows for use within a
range of settings, including labs that have previously not had the expertise
to conduct sequencing in-house. The initial application of the workflow will
focus on infectious disease, specifically the profiling of bacterial and
fungal pathogens using whole genome sequencing first from culture isolates and
eventually directly from positive blood cultures. The collaboration has the
potential to expand into additional infectious disease use cases, other areas
such as cancer and human genetics, and eventually regulatory approved clinical
diagnostics.

 

Vitor Rocha, President of Cepheid, commented:

"Combining the ease-of-use of the GeneXpert system, the most widely placed PCR
diagnostic instrument world-wide, with Oxford Nanopore's unique sequencing
platform, unlocks a richness of biomarker data that has historically been
technically challenging for many labs to access. Providing an integrated
solution to more effectively characterise infectious diseases, understand the
epidemiology of bacterial outbreaks, and profile antimicrobial resistance will
meaningfully accelerate our mission of expanding access to critical molecular
information. The potential for future expansion of this technology to
applications for patient care is exciting."

 

Dr Gordon Sanghera, CEO of Oxford Nanopore commented:

"This collaboration represents an important step forward in delivering new and
improved workflow options to better understand infectious diseases. By
partnering to integrate our richer data, rapid insights, and accessible and
affordable sequencing technology with Cepheid's GeneXpert architecture, we are
establishing a workflow foundation that is positioned for future expansion
into scaled routine clinical use."

 

The joint workflow will be compatible with a range of third-party informatics
tools including Oxford Nanopore's EPI2ME, and other informatic solutions that
are part of Oxford Nanopore's compatible provider network. Cepheid will also
complement the joint workflow by directly offering an informatics solution,
which they will commercialise by way of a license from a leading industry
player.

 

 

 

-ENDS-

 

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:         ir@nanoporetech.com (mailto:ir@nanoporetech.com)

Media:              media@nanoporetech.com
(mailto:media@nanoporetech.com)

 

Teneo (communications adviser to the Company)

Tom Murray, Jo Blackshaw

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com
(mailto:OxfordNanoporeTechnologies@teneo.com)

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The company
has developed a new generation of nanopore-based sensing technology for
faster, information rich, accessible and affordable molecular analysis. The
first application is DNA/RNA sequencing, and the technology is in development
for the analysis of other types of molecules including proteins. The
technology is used in more than 125 countries to understand and characterise
the biology of humans and diseases such as cancer, plants, animals, bacteria,
viruses, and whole environments. Oxford Nanopore Technologies products are
intended for molecular biology applications and are not intended for
diagnostic purposes. For more, visit: https://nanoporetech.com/
(https://nanoporetech.com/)

 

About Cepheid

Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company
that is an operating company within Danaher Corporation's Diagnostics
platform. Cepheid is dedicated to improving healthcare by developing,
manufacturing, and marketing accurate yet easy-to-use molecular systems and
tests. By automating highly complex and time-consuming manual procedures, the
company's solutions deliver a better way for institutions of any size to
perform sophisticated genetic testing for organisms and genetic-based
diseases. Through its strong molecular biology capabilities, the company is
focusing on those applications where accurate, rapid, and actionable test
results are needed most, such as managing infectious diseases and cancer. For
more information, visit http://www.cepheid.com (http://www.cepheid.com) .

 

Forward-looking statements

This announcement contains certain forward-looking statements. For example,
statements regarding expected revenue growth and profit margins are
forward-looking statements. Phrases such as "aim", "plan", "expect", "intend",
"anticipate", "believe", "estimate", "target", and similar expressions of a
future or forward-looking nature should also be considered forward-looking
statements. Forward-looking statements address our expected future business
and financial performance and financial condition, and by definition address
matters that are, to different degrees, uncertain. Our results could be
affected by macroeconomic conditions, delays or challenges in manufacturing or
delivering of products to our customers, suspensions of large projects and/or
acceleration of large products or accelerated adoption of pathogen
surveillance or applied uses of our products. These or other uncertainties may
cause our actual future results to be materially different than those
expressed in our forward-looking statements.

 1  For Research Use Only. Not for use in diagnostic procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUKVRRVAUSRAR